$SIBN
SI-BONE Inc

2021 Q2 Form 10-Q Financial Statement

#000145983921000054 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $22.19M $14.05M
YoY Change 57.98% -13.9%
Cost Of Revenue $2.375M $2.117M
YoY Change 12.19% 33.31%
Gross Profit $19.82M $11.93M
YoY Change 66.1% -18.99%
Gross Profit Margin 89.3% 84.93%
Selling, General & Admin $29.64M $19.91M
YoY Change 48.87% -4.85%
% of Gross Profit 149.53% 166.83%
Research & Development $3.149M $2.165M
YoY Change 45.45% 11.25%
% of Gross Profit 15.89% 18.14%
Depreciation & Amortization $500.0K $300.0K
YoY Change 66.67% 50.0%
% of Gross Profit 2.52% 2.51%
Operating Expenses $32.78M $22.07M
YoY Change 48.54% -3.48%
Operating Profit -$12.97M -$10.14M
YoY Change 27.87% 24.59%
Interest Expense $1.075M $2.683M
YoY Change -59.93% 117.6%
% of Operating Profit
Other Income/Expense, Net $13.00K $21.00K
YoY Change -38.1% -4.55%
Pretax Income -$13.98M -$12.47M
YoY Change 12.12% 44.16%
Income Tax
% Of Pretax Income
Net Earnings -$13.98M -$12.47M
YoY Change 12.1% 44.12%
Net Earnings / Revenue -62.99% -88.78%
Basic Earnings Per Share -$0.42 -$0.44
Diluted Earnings Per Share -$0.42 -$0.44
COMMON SHARES
Basic Shares Outstanding 32.98M shares 28.49M shares
Diluted Shares Outstanding 32.98M shares 28.49M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $176.6M $137.7M
YoY Change 28.3% 33.3%
Cash & Equivalents $48.13M $66.17M
Short-Term Investments $128.5M $71.50M
Other Short-Term Assets $2.434M $1.600M
YoY Change 52.13% -15.79%
Inventory $8.151M $4.969M
Prepaid Expenses
Receivables $11.89M $10.26M
Other Receivables $0.00 $0.00
Total Short-Term Assets $199.1M $154.5M
YoY Change 28.85% 29.84%
LONG-TERM ASSETS
Property, Plant & Equipment $7.868M $4.407M
YoY Change 78.53% 74.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $352.0K $312.0K
YoY Change 12.82% 0.65%
Total Long-Term Assets $8.220M $4.719M
YoY Change 74.19% -41.77%
TOTAL ASSETS
Total Short-Term Assets $199.1M $154.5M
Total Long-Term Assets $8.220M $4.719M
Total Assets $207.3M $159.2M
YoY Change 30.19% 25.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.918M $2.455M
YoY Change 59.59% 0.2%
Accrued Expenses $8.706M $9.272M
YoY Change -6.1% 24.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $12.62M $11.73M
YoY Change 7.65% 18.23%
LONG-TERM LIABILITIES
Long-Term Debt $39.63M $39.26M
YoY Change 0.93% 0.44%
Other Long-Term Liabilities $880.0K $389.0K
YoY Change 126.22% 7.16%
Total Long-Term Liabilities $40.51M $39.65M
YoY Change 2.16% 0.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.62M $11.73M
Total Long-Term Liabilities $40.51M $39.65M
Total Liabilities $53.13M $51.38M
YoY Change 3.41% 4.06%
SHAREHOLDERS EQUITY
Retained Earnings -$265.5M -$220.8M
YoY Change 20.23% 26.06%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $154.2M $107.9M
YoY Change
Total Liabilities & Shareholders Equity $207.3M $159.2M
YoY Change 30.19% 25.27%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$13.98M -$12.47M
YoY Change 12.1% 44.12%
Depreciation, Depletion And Amortization $500.0K $300.0K
YoY Change 66.67% 50.0%
Cash From Operating Activities -$8.150M -$7.870M
YoY Change 3.56% -6.2%
INVESTING ACTIVITIES
Capital Expenditures -$2.211M -$380.0K
YoY Change 481.84% -20.83%
Acquisitions
YoY Change
Other Investing Activities $18.79M $7.100M
YoY Change 164.65% 14.15%
Cash From Investing Activities $16.57M $6.720M
YoY Change 146.56% 17.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.217M -250.0K
YoY Change -986.8% -116.34%
NET CHANGE
Cash From Operating Activities -8.150M -7.870M
Cash From Investing Activities 16.57M 6.720M
Cash From Financing Activities 2.217M -250.0K
Net Change In Cash 10.64M -1.400M
YoY Change -859.71% 25.0%
FREE CASH FLOW
Cash From Operating Activities -$8.150M -$7.870M
Capital Expenditures -$2.211M -$380.0K
Free Cash Flow -$5.939M -$7.490M
YoY Change -20.71% -5.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001459839
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38701
dei Entity Registrant Name
EntityRegistrantName
SI-BONE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2216351
dei Entity Address Address Line1
EntityAddressAddressLine1
471 El Camino Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 101
dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95050
dei City Area Code
CityAreaCode
408
dei Local Phone Number
LocalPhoneNumber
207-0700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SIBN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33271020 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48125000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53581000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
128508000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
142851000 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
264000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
263000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11894000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13611000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
8151000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
5633000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2434000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2565000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
199112000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
218241000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7868000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4527000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
352000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
374000 USD
CY2021Q2 us-gaap Assets
Assets
207332000 USD
CY2020Q4 us-gaap Assets
Assets
223142000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3918000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3271000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8706000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10199000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12624000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13470000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39630000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39455000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
880000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
854000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
53134000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
53779000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2165000 USD
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33236270 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33236270 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32583220 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32583220 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
419235000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
408113000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
460000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
524000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265500000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239277000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
154198000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
169363000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207332000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223142000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14049000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22194000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42636000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30870000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2375000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2117000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4575000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4049000 USD
CY2021Q2 us-gaap Gross Profit
GrossProfit
19819000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
11932000 USD
us-gaap Gross Profit
GrossProfit
38061000 USD
us-gaap Gross Profit
GrossProfit
26821000 USD
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23084000 USD
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15755000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
44006000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
35036000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3149000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6104000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6551000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4255000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4151000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12491000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9551000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
32784000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
22071000 USD
us-gaap Operating Expenses
OperatingExpenses
62601000 USD
us-gaap Operating Expenses
OperatingExpenses
48842000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12965000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10139000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-24540000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-22021000 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
329000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
107000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
827000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
1075000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
2683000 USD
us-gaap Interest Expense
InterestExpense
2139000 USD
us-gaap Interest Expense
InterestExpense
3914000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
349000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-136000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13981000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-12472000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26223000 USD
us-gaap Net Income Loss
NetIncomeLoss
-25244000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
35000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-80000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
10000 USD
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4257000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-85000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
16000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
136000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13951000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12559000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26287000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25098000 USD
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32978914 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32978914 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28492582 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28492582 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32836040 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32836040 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27872505 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27872505 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
169363000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
601000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4030000 USD
CY2021Q1 sibn Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
9000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-115000 USD
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
21000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12242000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
161667000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
650000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1566000 USD
CY2021Q2 sibn Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
9000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
35000 USD
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13981000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
154198000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
63008000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62978000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2622000 USD
CY2020Q1 sibn Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
27000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
12000 USD
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
221000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12772000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
116270000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
991000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2955000 USD
CY2020Q2 sibn Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
26000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-85000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-12472000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
107868000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26223000 USD
us-gaap Net Income Loss
NetIncomeLoss
-25244000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8287000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5577000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
845000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
505000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
200000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-721000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
20000 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-500000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-157000 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
43000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
175000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
100000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1534000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-125000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-80000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1746000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1287000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2482000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-875000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
554000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-290000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1415000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2289000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1264000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9449000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17510000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17228000 USD
sibn Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
56977000 USD
sibn Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
33500000 USD
sibn Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0 USD
sibn Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
12592000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
43337000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34768000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4191000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10060000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62978000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
45297000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
45297000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
589000 USD
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0 USD
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
843000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1566000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
991000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1251000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
359000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2817000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62896000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-212000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5456000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55734000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53581000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10435000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48125000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66169000 USD
sibn Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
18000 USD
sibn Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
53000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
106000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
145000 USD
sibn Debt Issuance Costs Incurred But Not Yet Paid
DebtIssuanceCostsIncurredButNotYetPaid
0 USD
sibn Debt Issuance Costs Incurred But Not Yet Paid
DebtIssuanceCostsIncurredButNotYetPaid
161000 USD
us-gaap Nature Of Operations
NatureOfOperations
The Company and Nature of Business<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company received $63.0 million of net proceeds from its first follow-on public offering of 4,300,000 shares of the Company's common stock, of which 2,490,053 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 645,000 shares of the Company's common stock, at a public offering price of $21.50 per share. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $0.4 million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2 million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received $71.6 million of net proceeds from its second follow-on public offering of shares of the Company's common stock, of which 3,000,000 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 478,507 shares of the Company's common stock, at a public offering price of $22.00 per share. In addition to the shares sold by the Company in this second follow-on offering, the selling stockholder sold 190,053 shares of the Company's common stock previously held by the selling stockholder at a price to the public of $22.00 per share. The Company did not receive any proceeds from the sale by the selling stockholder. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to continuing risk and uncertainties as a result of the COVID-19 pandemic, and is closely monitoring the impact of the pandemic on all aspects of its business, including the impacts on its customers, patients that would benefit from utilizing the Company's products, employees, suppliers, vendors, business partners and distribution channels. Economies worldwide continue to be negatively impacted by the COVID-19 pandemic, in particular with recurrent outbreaks and mutations of the virus, despite advances in vaccines, and the Company anticipates these disruptions will continue. As such the Company's future results of operations and liquidity could be adversely impacted by a variety of factors related to the COVID-19 pandemic, including those discussed in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2020. As of the date of issuance of these condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors and uncertainty of market acceptance of products. The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22194000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14049000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42636000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30870000 USD
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
44653000 USD
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
44653000 USD
CY2021Q2 sibn Available For Sale Debt Securities Current Amortized Cost Basis
AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
128497000 USD
CY2021Q2 sibn Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
12000 USD
CY2021Q2 sibn Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
1000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
128508000 USD
CY2021Q2 sibn Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
173150000 USD
CY2021Q2 sibn Marketable Securities Accumulated Gross Unrealized Gain Before Tax
MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000 USD
CY2021Q2 sibn Marketable Securities Accumulated Gross Unrealized Loss Before Tax
MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 USD
CY2021Q2 sibn Marketable Securities Fair Value
MarketableSecuritiesFairValue
173161000 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
47348000 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
47348000 USD
CY2020Q4 sibn Available For Sale Debt Securities Current Amortized Cost Basis
AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis
142856000 USD
CY2020Q4 sibn Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax
8000 USD
CY2020Q4 sibn Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax
13000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
142851000 USD
CY2020Q4 sibn Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
190204000 USD
CY2020Q4 sibn Marketable Securities Accumulated Gross Unrealized Gain Before Tax
MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000 USD
CY2020Q4 sibn Marketable Securities Accumulated Gross Unrealized Loss Before Tax
MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000 USD
CY2020Q4 sibn Marketable Securities Fair Value
MarketableSecuritiesFairValue
190199000 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13635000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9484000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5767000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4957000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7868000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4527000 USD
CY2021Q2 us-gaap Depreciation
Depreciation
500000 USD
CY2020Q2 us-gaap Depreciation
Depreciation
300000 USD
us-gaap Depreciation
Depreciation
800000 USD
us-gaap Depreciation
Depreciation
500000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7495000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9175000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
459000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
511000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
752000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
513000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8706000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10199000 USD
CY2021Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000 USD
CY2020Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000 USD
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
576000 USD
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1091000 USD
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
995000 USD
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
926000 USD
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
385000 USD
CY2021Q2 sibn Operating Leases Future Minimum Payments Due After Year Four
OperatingLeasesFutureMinimumPaymentsDueAfterYearFour
24000 USD
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3997000 USD
CY2021Q2 us-gaap Purchase Obligation
PurchaseObligation
1800000 USD
CY2020Q4 us-gaap Purchase Obligation
PurchaseObligation
300000 USD
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
41000000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
41000000 USD
CY2021Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
587000 USD
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
661000 USD
CY2021Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
783000 USD
CY2020Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
884000 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
39630000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
39455000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39630000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39455000 USD
CY2020 sibn Write Off Of Deferred Debt Issuance Cost And Debt Discount
WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount
700000 USD
CY2020 sibn Prepayment Penalty And Lender Fees In Extinguishment Of Debt
PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt
800000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
11667000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
9333000 USD
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
41000000 USD
CY2020Q4 sibn Social Security Tax Employer Deferral Cares Act
SocialSecurityTaxEmployerDeferralCARESAct
1000000.0 USD
CY2021Q2 sibn Social Security Tax Employer Deferral Cares Act
SocialSecurityTaxEmployerDeferralCARESAct
1000000.0 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2405957 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.54
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
234892 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
23170 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.02
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2147895 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.81
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.37
CY2021Q2 sibn Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase
1945 shares
CY2020Q4 sibn Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase
5836 shares
us-gaap Net Income Loss
NetIncomeLoss
-25244000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4257000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2955000 USD
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32978914 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8287000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5577000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13981000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-12472000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26223000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32978914 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28492582 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28492582 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32836040 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32836040 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27872505 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27872505 shares
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4021396 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4238304 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4021396 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4238304 shares

Files In Submission

Name View Source Status
0001459839-21-000054-index-headers.html Edgar Link pending
0001459839-21-000054-index.html Edgar Link pending
0001459839-21-000054.txt Edgar Link pending
0001459839-21-000054-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rms_sibonexarmqsax61121xre.htm Edgar Link pending
Show.js Edgar Link pending
sibn-20210630.htm Edgar Link pending
sibn-20210630.xsd Edgar Link pending
sibn-20210630_cal.xml Edgar Link unprocessable
sibn-20210630_def.xml Edgar Link unprocessable
sibn-20210630_htm.xml Edgar Link completed
sibn-20210630_lab.xml Edgar Link unprocessable
sibn-20210630_pre.xml Edgar Link unprocessable
sibn-ex311_630202110xq.htm Edgar Link pending
sibn-ex312_630202110xq.htm Edgar Link pending
sibn-ex321_630202110xq.htm Edgar Link pending